Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

AKBA 11.12.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-21
Name of Upcoming Event:Jefferies London Healthcare Conference
Full Press ReleaseSEC FilingsOur AKBA Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Akebia Therapeutics Announces Multiple Positive Business Updates
  • 01.02.2025 - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report

CAMBRIDGE, Mass.,Nov. 12, 2024/PRNewswire/ --Akebia Therapeutics®, Inc.(Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced thatJohn Butler, Chief Executive Officer, will present at theJefferies London Healthcare ConferenceonThursday, November 21at1:00 PM GMT.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)

A webcast of the presentation can be accessed through the "Investors" section of Akebia's website athttps://ir.akebia.comfor 30 days following the conference.

The Jefferies London Healthcare Conferencewill take placeNovember 19-21, 2024inLondon.

AboutAkebia TherapeuticsAkebia Therapeutics, Inc.is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered inCambridge, Massachusetts. For more information, please visit our website atwww.akebia.com, which does not form a part of this release.

Akebia Therapeutics ContactMercedes Carrascomcarrasco@akebia.com

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-jefferies-london-healthcare-conference-302301773.html

SOURCEAkebia Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com